Advertisement
-- ThinkEquity Partners' 5th Annual Growth Conference at the St. RegisHotel in San Francisco on Tuesday, September 18th at 8:30 a.m. PDT.
-- Maxim Group's 1st Annual Growth Conference at the Grand Hyatt Hotel inNew York City on Thursday, September 20th at 3:30 p.m. EDT.
Advertisement
Both presentations will be made available by webcast and can be accessedon the Media page of Response Genetics' website at www.responsegenetics.com.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the researchand development of pharmacogenomic cancer diagnostic tests based on itsproprietary and patented technologies. RGI's technologies enable extractionand analysis of genetic information from genes derived from tumor samplesstored as formalin-fixed and paraffin embedded specimens. RGI currentlygenerates revenue primarily from the sales of its proprietary analyticalpharmacogenomic testing services of clinical trial specimens to thepharmaceutical industry. The company was founded in 1999 and its principalheadquarters are located in Los Angeles, California. For more information,please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press releaseand the statements of representatives of Response Genetics, Inc. (the"Company") related thereto contain or may contain, among other things, certainforward-looking statements, within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such forward-looking statements involvesignificant risks and uncertainties. Such statements may include, withoutlimitation, statements with respect to the Company's plans, objectives,projections, expectations and intentions, and other statements identified bywords such as "projects", "may", "could", "would", "should", "believes","expects", "anticipates", "estimates", "intends", "plans" or similarexpressions. These statements are based upon the current beliefs andexpectations of the Company's management and are subject to significant risksand uncertainties, including those detailed in the Company's filings with theSecurities and Exchange Commission. Actual results, including, withoutlimitation, actual sales results, if any, or the application of funds, maydiffer from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject tochange based on various factors (many of which are beyond the Company'scontrol). The Company undertakes no obligation to publicly update forwardlooking statements, whether because of new information, future events orotherwise, except as required by law.
SOURCE Response Genetics, Inc.
